Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

videos

Andrew Yee, MD
Videos
Selecting Optimal Treatments for Patients With Relapsed Multiple Myeloma
09/06/2023

Featuring Andrew Yee, MD

Featuring Andrew Yee, MD
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Yee, MD, discusses treatment options for patients with relapsed MM, including anti-CD38 antibodies, cyclophosphamide-based combinations, and BCL-2 inhibitors.
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Yee, MD, discusses treatment options for patients with relapsed MM, including anti-CD38 antibodies, cyclophosphamide-based combinations, and BCL-2 inhibitors.
At the 2023 Great Debates &...
09/06/2023
Oncology
Andrew Evens, DO, MBA, MSc
Videos
Antibody Drug Conjugates for the Frontline Treatment of Patients With Advanced-Stage Hodgkin Lymphoma
09/05/2023

Featuring Andrew Evens, DO, MBA, MSc

Featuring Andrew Evens, DO, MBA, MSc ...
Andrew Evens, DO, MBA, MSc, analyzes the first-line treatment landscape for patients with advanced-stage Hodgkin lymphoma through the integration of antibody drug conjugates, at the 2023 Great Debates & Updates in Hematologic Malignancies...
Andrew Evens, DO, MBA, MSc, analyzes the first-line treatment landscape for patients with advanced-stage Hodgkin lymphoma through the integration of antibody drug conjugates, at the 2023 Great Debates & Updates in Hematologic Malignancies...
Andrew Evens, DO, MBA, MSc,...
09/05/2023
Oncology
Daniel DeAngelo, MD, PhD
Videos
Promising Outcomes of FGFR1 Inhibitor Pemigatinib for Myeloid Lymphoid Neoplasms
08/28/2023

Featuring Daniel DeAngelo, MD, PhD

Featuring Daniel DeAngelo, MD, PhD ...
Daniel DeAngelo, MD, PhD, presents data on the promising outcomes of pemigatinib, an FGFR1 inhibitor, among patients with myeloid lymphoid neoplasms, at the 2023 Great Debates & Updates in Hematologic Malignancies meeting.
Daniel DeAngelo, MD, PhD, presents data on the promising outcomes of pemigatinib, an FGFR1 inhibitor, among patients with myeloid lymphoid neoplasms, at the 2023 Great Debates & Updates in Hematologic Malignancies meeting.
Daniel DeAngelo, MD, PhD,...
08/28/2023
Oncology
Peter Voorhees, MD
Videos
Examining CD38-Targeting Antibody Therapies for Patients With Newly Diagnosed Transplant-Ineligible Multiple Myeloma
08/28/2023

Featuring Peter Voorhees, MD

Featuring Peter Voorhees, MD
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Peter Voorhees, MD, analyzes data on the use of CD38-targeting antibodies for patients with newly diagnosed transplant-ineligible multiple myeloma.
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Peter Voorhees, MD, analyzes data on the use of CD38-targeting antibodies for patients with newly diagnosed transplant-ineligible multiple myeloma.
At the 2023 Great Debates &...
08/28/2023
Oncology
Andrew Evens, DO, MBA, MSc
Videos
Current Treatment Landscape for Patients With Relapsed/Refractory Hodgkin Lymphoma
08/24/2023

Featuring Andrew Evens, DO, MBA, MSc

Featuring Andrew Evens, DO, MBA, MSc ...
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Evens, DO, MBA, MSc, discusses current treatment options for patients with Hodgkin lymphoma after relapse occurs.
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Evens, DO, MBA, MSc, discusses current treatment options for patients with Hodgkin lymphoma after relapse occurs.
At the 2023 Great Debates &...
08/24/2023
Oncology
Monique Hartley-Brown, MD, MMSc
Videos
Emergent Therapies for Patients With Relapsed/Refractory Multiple Myeloma
08/24/2023

Featuring Monique Hartley-Brown, MD, MMSc

Featuring Monique Hartley-Brown, MD, ...
Monique Hartley-Brown, MD, MMSc, presents her insights into treatment developments for patients with relapsed/refractory multiple myeloma, a topic which she discussed at the 2023 Great Debates & Updates in Hematologic Malignancies meeting.
Monique Hartley-Brown, MD, MMSc, presents her insights into treatment developments for patients with relapsed/refractory multiple myeloma, a topic which she discussed at the 2023 Great Debates & Updates in Hematologic Malignancies meeting.
Monique Hartley-Brown, MD, MMSc,...
08/24/2023
Oncology
Amir Fathi, MD
Videos
Incorporating IDH and Menin Inhibitors as Therapies for Subsets of Patients With AML
08/22/2023

Featuring Amir Fathi, MD

Featuring Amir Fathi, MD
At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, Amir Fathi, MD, shares insights on the emergence of IDH and menin inhibitors as therapies to target certain subsets of patients with acute myeloid leukemia.
At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, Amir Fathi, MD, shares insights on the emergence of IDH and menin inhibitors as therapies to target certain subsets of patients with acute myeloid leukemia.
At the 2023 Great Debates &...
08/22/2023
Oncology
Peter Voorhees, MD
Videos
Evolving Frontline Therapies for Patients With Newly Diagnosed Multiple Myeloma
08/22/2023

Featuring Peter Voorhees, MD

Featuring Peter Voorhees, MD
Peter Voorhees, MD, discusses the latest updates in frontline therapeutic options for patients with newly diagnosed MM, a topic which he presented on at the 2023 Great Debates & Updates in Hematologic Malignancies meeting.
Peter Voorhees, MD, discusses the latest updates in frontline therapeutic options for patients with newly diagnosed MM, a topic which he presented on at the 2023 Great Debates & Updates in Hematologic Malignancies meeting.
Peter Voorhees, MD, discusses...
08/22/2023
Oncology
Amer Zeidan, MBBS
Videos
New Developments in Risk Stratification and Management of High-Risk and Low-Risk MDS
08/19/2023

Featuring Amer Zeidan, MBBS

Featuring Amer Zeidan, MBBS
At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, Amer Zeidan, MBBS, speaks on recent developments in risk stratification and treatment management among patients with high-risk and low-risk myelodysplastic syndromes.
At the 2023 Great Debates & Updates in Hematologic Malignancies Meeting, Amer Zeidan, MBBS, speaks on recent developments in risk stratification and treatment management among patients with high-risk and low-risk myelodysplastic syndromes.
At the 2023 Great Debates &...
08/19/2023
Oncology
Daniel DeAngelo, MD, PhD
Videos
Diagnosing and Treating Patients With Indolent and Advanced Systemic Mastocytosis
08/19/2023

Featuring Daniel DeAngelo, MD, PhD

Featuring Daniel DeAngelo, MD, PhD ...
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Daniel DeAngelo, MD, PhD, shares insights into recent treatment developments and diagnostic criteria for patients with indolent and systemic mastocytosis.
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Daniel DeAngelo, MD, PhD, shares insights into recent treatment developments and diagnostic criteria for patients with indolent and systemic mastocytosis.
At the 2023 Great Debates &...
08/19/2023
Oncology

Advertisement

About

At Great Debates and Updates in Hematologic Malignancies, nationally recognized thought leaders take opposing sides on clinical—and sometimes controversial—topics currently disrupting the practice of hematology and oncology.

Through comprehensive review of the latest clinical advancements in hematologic malignancies, robust audience engagement, and ample discussion, participants will leave equipped with practical implications and applications to put into practice immediately.

Platinum Sponsors

johnson & johnson

 

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use